Our model suggests that ctDNA could improve clinical decision-making for stage I NSCLC. Prospectively identified high-risk patients could benefit from systemic therapy. We assumed that occult micrometastases and ctDNA had clinical significance, which is supported in published literature.
(P026) Is Cause-Specific Survival Similar for Estrogen Receptor- and Progesterone Receptor-Negative Early-Stage Invasive Lobular and Invasive Ductal Cancers? A National Registry SEER Database Study
For early-stage breast cancer cases with ER+ and PR+ status, histology was not associated with a difference in BCSS. Alternatively, ILC cases that were ER− or PR− had an increased BCSS compared with receptor-matched IDC cases. These findings add to the growing evidence supporting ILC as a more favorable histology, which is important for guiding treatment and prognostication.
(P043) Central Neurocytoma: Impact of Resection Extent and Adjuvant Radiotherapy on Survival Outcomes
Adjuvant RT was delivered to a minority of CNC patients after either GTR or STR in this national database, though patients were more likely to receive RT after STR. Long-term OS was excellent for all subgroups, and there was no clear evidence of resection extent or adjuvant RT influencing survival outcomes. Since our database is subject to selection bias and limited by a lack of information regarding local recurrence, salvage therapies, exact extent of STR, and RT technique, further research is needed to validate our findings.
(P096) Late Radiation-Associated Dysphagia (Late-RAD) With Lower Cranial Neuropathy After Oropharyngeal IMRT
Although the majority of oropharyngeal cancer survivors enjoy functional recovery in early survivorship, almost 10% suffer severe, late deterioration of swallowing abilities. Delayed lower cranial neuropathies often precipitate late-RAD.
This is the largest reported series of AFX treated with radiation therapy in the literature. No contraindication to the use of radiation is found in the literature. Prior series all utilized surgery, likely due to the clinically rapid progression of this tumor. Risk of recurrence is mitigated with surgical debulking prior to brachytherapy. Electronic brachytherapy appears to be a safe and effective treatment for AFX.
(P130) An Exploratory Pilot Study of Perfusion Patterns in Locoregionally Advanced Head and Neck Cancer Using a Novel Analysis Technique of Dynamic Contrast-Enhanced (DCE)-MRI
UPR is a novel technique that has been developed in a preclinical tumor model and that is potentially applicable in HNCs. This exploratory study appears consistently to identify subvolumes within the GTV that may have therapeutic implications and that may be promising areas for further research (eg, correlation with hypoxia and clinical outcome).
(P057) A Population-Based Study of Men With Low-Volume, Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?
In this large population-based cohort of 1,794 men with low-risk, low-volume prostate cancer, AA race was not associated with more aggressive pathology compared with Caucasians.
(P070) High-Risk Prostate Adenocarcinoma Treated With Whole-Pelvis Radiotherapy HDR Brachytherapy Boost Results in Very High Disease-Specific Survival
Pelvic radiotherapy followed by HDR brachytherapy boost is an effective treatment for high-risk prostate cancer. It provides excellent long-term disease control and very low rates of severe (grade ≥ 3) toxicity when delivered in two or three fractions.
OGCC can exhibit aggressive progression, warranting investigation into multimodal therapy. Given that adjuvant chemoradiation and immunotherapy are associated with improved outcomes in primary head and neck cancer, a similar application in OGCC may help guide optimal treatment. This approach was well tolerated in our pediatric patient, and he remains disease-free at 14 months.
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
SBRT is an effective treatment modality, achieving excellent local control with minimal toxicity for patients with adrenal metastases. The development of progressive distant metastasis is the predominant pattern of failure affecting patients’ survival outcomes.